JNJ-54781532-AAD-10 mg ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎7

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-000263-88-RO
(EUCTR)
03/09/201430/05/2014A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
INN or Proposed INN: Not available
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
INN or Proposed INN: Not available
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
INN or Proposed INN: Not available
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2United States;France;Hungary;Canada;Poland;Belgium;Ukraine;Romania;Russian Federation;Bulgaria;Netherlands;Germany
2EUCTR2013-000263-88-BG
(EUCTR)
14/04/201417/02/2014A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2France;United States;Hungary;Canada;Poland;Belgium;Ukraine;Romania;Russian Federation;Bulgaria;Netherlands;Germany
3EUCTR2013-000263-88-PL
(EUCTR)
29/01/201426/11/2013A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2United States;France;Hungary;Canada;Belgium;Poland;Ukraine;Romania;Bulgaria;Russian Federation;Germany;Netherlands
4EUCTR2013-000263-88-NL
(EUCTR)
23/01/201421/11/2013A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2United States;France;Hungary;Canada;Belgium;Poland;Ukraine;Romania;Bulgaria;Russian Federation;Germany;Netherlands
5EUCTR2013-000263-88-HU
(EUCTR)
16/01/201421/11/2013A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2France;United States;Hungary;Canada;Poland;Belgium;Ukraine;Romania;Russian Federation;Bulgaria;Netherlands;Germany
6EUCTR2013-000263-88-BE
(EUCTR)
08/01/201429/10/2013A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2United States;Ukraine;Russian Federation;Israel;France;Hungary;Canada;Belgium;Poland;Romania;Australia;Bulgaria;Germany;Netherlands
7EUCTR2013-000263-88-DE
(EUCTR)
07/01/201414/10/2013A study to evaluate the dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis Ulcerative Colitis
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: JNJ-54781532-AAD-5 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-10 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Product Name: JNJ-54781532-AAD-30 mg
INN or Proposed INN: Not Assigned
Other descriptive name: ASP015K
Janssen-Cilag International NVNULLNot RecruitingFemale: yes
Male: yes
220Phase 2France;United States;Hungary;Canada;Poland;Belgium;Ukraine;Romania;Russian Federation;Bulgaria;Netherlands;Germany